89bio Inc has a consensus price target of $27.36, established from looking at the 56 latest analyst ratings. The last 3 analyst ratings were released from B of A Securities, Cantor Fitzgerald, and HC Wainwright & Co. on April 22, 2024, April 5, 2024, and March 27, 2024. With an average price target of $30 between B of A Securities, Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 263.64% upside for 89bio Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/22/2024 | ETNB | Buy Now | 89bio | $8.25 | 263.64% | B of A Securities | Alexandria Hammond | → $30 | Assumes | → Buy | Get Alert |
04/05/2024 | ETNB | Buy Now | 89bio | $8.25 | 251.52% | Cantor Fitzgerald | Kristen Kluska | → $29 | Reiterates | Overweight → Overweight | Get Alert |
03/27/2024 | ETNB | Buy Now | 89bio | $8.25 | 275.76% | HC Wainwright & Co. | Ed Arce | $31 → $31 | Maintains | Buy | Get Alert |
03/13/2024 | ETNB | Buy Now | 89bio | $8.25 | 275.76% | HC Wainwright & Co. | Ed Arce | $31 → $31 | Maintains | Buy | Get Alert |
03/07/2024 | ETNB | Buy Now | 89bio | $8.25 | 348.48% | Evercore ISI Group | Liisa Bayko | $29 → $37 | Maintains | Outperform | Get Alert |
03/06/2024 | ETNB | Buy Now | 89bio | $8.25 | 348.48% | Evercore ISI Group | Liisa Bayko | $29 → $37 | Maintains | Outperform | Get Alert |
03/05/2024 | ETNB | Buy Now | 89bio | $8.25 | — | Oppenheimer | Jay Olson | — | Maintains | Perform | Get Alert |
03/04/2024 | ETNB | Buy Now | 89bio | $8.25 | 251.52% | Cantor Fitzgerald | Kristen Kluska | → $29 | Reiterates | Overweight → Overweight | Get Alert |
03/01/2024 | ETNB | Buy Now | 89bio | $8.25 | 69.7% | RBC Capital | Brian Abrahams | $15 → $14 | Maintains | Sector Perform | Get Alert |
03/01/2024 | ETNB | Buy Now | 89bio | $8.25 | 275.76% | HC Wainwright & Co. | Ed Arce | $32 → $31 | Maintains | Buy | Get Alert |
01/12/2024 | ETNB | Buy Now | 89bio | $8.25 | 81.82% | RBC Capital | Brian Abrahams | → $15 | Downgrade | Outperform → Sector Perform | Get Alert |
12/20/2023 | ETNB | Buy Now | 89bio | $8.25 | 287.88% | HC Wainwright & Co. | Ed Arce | $35 → $32 | Maintains | Buy | Get Alert |
12/05/2023 | ETNB | Buy Now | 89bio | $8.25 | 324.24% | HC Wainwright & Co. | Ed Arce | → $35 | Reiterates | Buy → Buy | Get Alert |
11/28/2023 | ETNB | Buy Now | 89bio | $8.25 | 324.24% | HC Wainwright & Co. | Ed Arce | → $35 | Reiterates | Buy → Buy | Get Alert |
11/09/2023 | ETNB | Buy Now | 89bio | $8.25 | 190.91% | RBC Capital | Brian Abrahams | $27 → $24 | Maintains | Outperform | Get Alert |
10/12/2023 | ETNB | Buy Now | 89bio | $8.25 | 203.03% | UBS | Eliana Merle | $36 → $25 | Maintains | Buy | Get Alert |
10/11/2023 | ETNB | Buy Now | 89bio | $8.25 | 227.27% | RBC Capital | Brian Abrahams | $34 → $27 | Maintains | Outperform | Get Alert |
09/22/2023 | ETNB | Buy Now | 89bio | $8.25 | 312.12% | RBC Capital | Brian Abrahams | → $34 | Reiterates | Outperform → Outperform | Get Alert |
08/28/2023 | ETNB | Buy Now | 89bio | $8.25 | 336.36% | UBS | Eliana Merle | → $36 | Initiates | → Buy | Get Alert |
The latest price target for 89bio (NASDAQ: ETNB) was reported by B of A Securities on April 22, 2024. The analyst firm set a price target for $30.00 expecting ETNB to rise to within 12 months (a possible 263.64% upside). 28 analyst firms have reported ratings in the last year.
The latest analyst rating for 89bio (NASDAQ: ETNB) was provided by B of A Securities, and 89bio their buy rating.
The last upgrade for 89bio Inc happened on May 12, 2022 when Raymond James raised their price target to $12. Raymond James previously had an outperform for 89bio Inc.
The last downgrade for 89bio Inc happened on January 12, 2024 when RBC Capital changed their price target from N/A to $15 for 89bio Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 89bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 89bio was filed on April 22, 2024 so you should expect the next rating to be made available sometime around April 22, 2025.
While ratings are subjective and will change, the latest 89bio (ETNB) rating was a with a price target of $0.00 to $30.00. The current price 89bio (ETNB) is trading at is $8.25, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.